spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Sartorius debuts the Intellicyt iQue3 at CYTO® 2019

Sartorius Group


Sartorius will be showcasing the latest addition to its cellular analysis portfolio on booth #103 at this year’s CYTO® conference and exhibition, with the launch of the Intellicyt iQue3. The event – which takes place in Vancouver, Canada, from June 22 to 26 – will give delegates the chance to explore a smarter way to perform flow cytometry experiments.

The iQue3 is designed to provide fully automated processing and analysis for flow cytometry workflows, taking you from samples to actionable answers faster than ever before. Successor to the iQue Screener PLUS, the new generation instrument offers even more user-friendly operation and enhanced process security to ensure consistent and reliable results with minimal user intervention.

One of the iQue3’s new features is an enhanced rinse station that actively monitors buffer usage. With built-in liquid level detection, this module offers a smarter way to ensure you always have sufficient buffers to complete your run. This is complemented by a number of updates to the system’s intuitive ForeCyt software, which uses a unique templated analysis approach to offer intelligent, fully automated data processing. This powerful software solution has been specifically developed to alleviate common processing bottlenecks by eliminating the need for manual data analysis and providing real-time visualization of your data for virtually any cell- or bead-based assay.

To learn how to get from samples to actionable results in hours not days, go to www.sartorius.com/intellicyt or visit booth #103 at CYTO 2019.

About Sartorius
The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2018, Sartorius earned sales revenue of around 1.57 billion euros. Currently, some 8,500 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe. Visit www.sartorius.com/intellicyt

© 2019 kdm communications limited

Editorial contact for further information or follow-up
Sarah Khan at kdm communications limited, St Neots, UK
Tel. +44 (0)1480 405333 Fax: +44 (0)1480 477833
phone +49.551.308.0
email info@sartorius.com
web www.sartorius.com
email Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

ERT Virtual Visit Capabilities Keep Clinical Trials on Track during COVID-19

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a Virtual Visit solution that enables the continuation of clinical trials during and after current global stay-at-home mandates. As a result of COVID-19, many clinical trials have been delayed as healthcare providers focus their efforts on patients who require urgent care, which limits clinical trial patients’ access to investigative sites for routine visits.
More info >>


White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement